This page shows the latest risdiplam news and features for those working in and with pharma, biotech and healthcare.
Genentech’s Evrysdi (risdiplam), a treatment for spinal muscular atrophy (SMA), has been given an extended approved by the US Food and Drug Administration (FDA) to include babies under two months
FIREFISH evaluated the efficacy and safety of Evrysdi (risdiplam) in infants aged 1-7 months at the time of enrolment with type 1 spinal muscular atrophy (SMA).
Evrysdi (risdiplam) is a drug designed to treat SMA through an increased and sustained production of the SMN protein – a vital protein for maintaining functioning motor neurons and movement – found throughout
deal. The National Institute for Health and Care Excellence (NICE) has recommended that Roche’s Evrysdi (risdiplam) be made available to patients in England as part of a managed access agreement.
The EC has approved Evrysdi (risdiplam) for the treatment of SMA in patients aged two months or older who have a clinical diagnosis of SMA type 1, type 2, type 3
Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following
More from news
Approximately 6 fully matching, plus 22 partially matching documents found.
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...